Antiretroviral News and Research

RSS

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs.

1 Dec 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

The University of Texas Medical Branch is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the National Institutes of Health to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million.

26 Nov 2014

Study finds that starting ART treatment soon after HIV infection improves immune health

HIV-1-infected U.S. military members and beneficiaries treated with antiretroviral therapy (ART) soon after infection were half as likely to develop AIDS and were more likely to reconstitute their immune-fighting CD4+ T-cells to normal levels, researchers reported Nov. 24 in JAMA Internal Medicine.

25 Nov 2014

Novel method could improve treatment for infants, young children suffering from HIV/AIDS

A novel method of altering a protein in milk to bind with an antiretroviral drug promises to greatly improve treatment for infants and young children suffering from HIV/AIDS, according to a researcher in Penn State's College of Agricultural Sciences.

12 Nov 2014

Successful treatments help HIV-infected persons achieve similar longevity as those without HIV

New research from the Johns Hopkins Bloomberg School of Public Health suggests that HIV-infected adults are at a higher risk for developing heart attacks, kidney failure and cancer. But, contrary to what many had believed, the researchers say these illnesses are occurring at similar ages as adults who are not infected with HIV.

11 Nov 2014

Mylan announces U.S. launch of generic Loestrin 24 Fe

Mylan Inc. today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe.

5 Nov 2014

New research sheds light on future efforts to eradicate HIV from the body in human patients

Where does HIV hide? Antiretroviral drugs can usually control the virus, but can't completely eliminate it. So any strategy to eradicate HIV from the body has to take into account not only the main group of immune cells the virus targets, called CD4 or helper T cells, but other infected cells as well.

3 Nov 2014

Dosing of antiretroviral medication to prevent HIV infection differs by sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex.

31 Oct 2014

CHOP, Temple University to jointly investigate new methods for eradicating HIV

The Children's Hospital of Philadelphia and Temple University have received a joint $4.3 million, four-year grant from the National Institute of Mental Health to investigate new methods to eradicate HIV that lurks in brain cells despite conventional antiviral treatments.

28 Oct 2014

New study reveals ways to reduce HIV rates in Mexico

To address the HIV epidemic in Mexico is to address it among men who have sex with men (MSM), because they account for a large percentage of the country's new infections, says Omar Galárraga, assistant professor of health services policy and practice in the Brown University School of Public Health.

16 Oct 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%.

14 Oct 2014

Research roundup: Older consumers' spending on health care; hospital leaders' views of reporting quality

In 2011, households with at least one member between ages 50 and 64 spent 8 percent of their total budget on health items, compared with 19 percent for those age 85 or over.

13 Oct 2014

HIV-infected users of stimulants derive benefits from antiretroviral therapy

New clinical research from UC San Francisco shows that 341 HIV-infected men who reported using stimulants such as methamphetamine or cocaine derived life-saving benefits from being on antiretroviral therapy that were comparable to those of HIV-infected men who do not use stimulants.

13 Oct 2014

Penn Medicine to explore therapeutic strategies for HIV positive women at risk of cervical cancer

The introduction of antiretroviral drugs in Botswana over the last two decades has increased the life expectancies of people living with HIV—many of whom are women co-infected with the human papillomavirus virus (HPV)—considerably: from 39 years to the low 60s. As a result, this co-infected group of women is at a much higher risk of developing HPV-associated cervical cancer.

7 Oct 2014

BIDMC receives $20 million grant to evaluate, test monoclonal antibodies for HIV treatment

Beth Israel Deaconess Medical Center has received a four-year, $20 million grant from the Bill & Melinda Gates Foundation to evaluate and test broadly neutralizing monoclonal antibodies for the treatment of HIV.

3 Oct 2014

UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

The UCSF Clinician Consultation Center at San Francisco General Hospital and Trauma Center has been funded by the Centers for Disease Control and Prevention to provide a PrEPline, a telephone consultation service that gives expert guidance to healthcare providers across the nation who prescribe antiretroviral medications to HIV uninfected individuals to prevent HIV.

30 Sep 2014

New NIH program awards $2.5 million to spur innovation in mobile health

A new NIH program is awarding nearly $2.5 million to spur innovation in mobile communication technologies and software applications used in biomedical research in low- and middle-income countries (LMICs).

25 Sep 2014

Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen Inc. announced today that PREZCOBIX (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. It is the first HIV treatment option available to patients that provides boosted darunavir in a single tablet.

17 Sep 2014

Miriam Hospital receives grant from NIH to prevent spread of sexually transmitted HIV in women

The Miriam Hospital is part of a research collaboration that has received a $20 million grant from the National Institutes of Health (NIH) to develop an intravaginal ring (IVR) that can deliver powerful antiretroviral (ARV) drugs to prevent the spread of sexually transmitted HIV in women.

9 Sep 2014